199 related articles for article (PubMed ID: 26644118)
1. Bisphosphonates and evidence for association with esophageal and gastric cancer: a systematic review and meta-analysis.
Wright E; Schofield PT; Molokhia M
BMJ Open; 2015 Dec; 5(12):e007133. PubMed ID: 26644118
[TBL] [Abstract][Full Text] [Related]
2. Bisphosphonates and risk of upper gastrointestinal cancer--a case control study using the General Practice Research Database (GPRD).
Wright E; Schofield PT; Seed P; Molokhia M
PLoS One; 2012; 7(10):e47616. PubMed ID: 23112825
[TBL] [Abstract][Full Text] [Related]
3. Bisphosphonate treatment and risk of esophageal cancer: a meta-analysis of observational studies.
Sun K; Liu JM; Sun HX; Lu N; Ning G
Osteoporos Int; 2013 Jan; 24(1):279-86. PubMed ID: 23052941
[TBL] [Abstract][Full Text] [Related]
4. Exposure to oral bisphosphonates and risk of esophageal cancer.
Cardwell CR; Abnet CC; Cantwell MM; Murray LJ
JAMA; 2010 Aug; 304(6):657-63. PubMed ID: 20699457
[TBL] [Abstract][Full Text] [Related]
5. Oral Bisphosphonates and Upper Gastrointestinal Cancer Risks in Asians with Osteoporosis: A Nested Case-Control Study Using National Retrospective Cohort Sample Data from Korea.
Jung SY; Sohn HS; Park EJ; Suh HS; Park JW; Kwon JW
PLoS One; 2016; 11(3):e0150531. PubMed ID: 26937968
[TBL] [Abstract][Full Text] [Related]
6. Bisphosphonate use and gastrointestinal tract cancer risk: meta-analysis of observational studies.
Oh YH; Yoon C; Park SM
World J Gastroenterol; 2012 Oct; 18(40):5779-88. PubMed ID: 23155320
[TBL] [Abstract][Full Text] [Related]
7. Esophageal and gastric cancer incidence and mortality in alendronate users.
Abrahamsen B; Pazianas M; Eiken P; Russell RG; Eastell R
J Bone Miner Res; 2012 Mar; 27(3):679-86. PubMed ID: 22113985
[TBL] [Abstract][Full Text] [Related]
8. Bisphosphonates and risk of lung cancer: Protocol for a systematic review and meta-analysis.
Li M; Zhong M; Guan C
Medicine (Baltimore); 2021 Jan; 100(1):e22839. PubMed ID: 33429726
[TBL] [Abstract][Full Text] [Related]
9. Exposure to bisphosphonates and risk of gastrointestinal cancers: series of nested case-control studies with QResearch and CPRD data.
Vinogradova Y; Coupland C; Hippisley-Cox J
BMJ; 2013 Jan; 346():f114. PubMed ID: 23325866
[TBL] [Abstract][Full Text] [Related]
10. An evaluation of the use of oral bisphosphonates and risk of esophageal cancer.
Haber SL; McNatty D
Ann Pharmacother; 2012 Mar; 46(3):419-23. PubMed ID: 22333262
[TBL] [Abstract][Full Text] [Related]
11. Bisphosphonates use and risk of gastric cancer: an updated meta-analysis of cohort and case-control studies.
Cai D; Qin J; Chen G; Feng W; Liu J
Minerva Med; 2017 Oct; 108(5):464-472. PubMed ID: 28466630
[TBL] [Abstract][Full Text] [Related]
12. Oral bisphosphonates and risk of cancer of oesophagus, stomach, and colorectum: case-control analysis within a UK primary care cohort.
Green J; Czanner G; Reeves G; Watson J; Wise L; Beral V
BMJ; 2010 Sep; 341():c4444. PubMed ID: 20813820
[TBL] [Abstract][Full Text] [Related]
13. Bisphosphonates and atrial fibrillation: systematic review and meta-analysis.
Loke YK; Jeevanantham V; Singh S
Drug Saf; 2009; 32(3):219-28. PubMed ID: 19338379
[TBL] [Abstract][Full Text] [Related]
14. Bisphosphonates for osteoporosis in primary biliary cirrhosis.
Rudic JS; Giljaca V; Krstic MN; Bjelakovic G; Gluud C
Cochrane Database Syst Rev; 2011 Dec; (12):CD009144. PubMed ID: 22161446
[TBL] [Abstract][Full Text] [Related]
15. More on reports of esophageal cancer with oral bisphosphonate use.
Shaheen NJ
N Engl J Med; 2009 Apr; 360(17):1790-1; author reply 1791-2. PubMed ID: 19391257
[No Abstract] [Full Text] [Related]
16. Risk of cardiac valvulopathy with use of bisphosphonates: a population-based, multi-country case-control study.
Coloma PM; de Ridder M; Bezemer I; Herings RM; Gini R; Pecchioli S; Scotti L; Rijnbeek P; Mosseveld M; van der Lei J; Trifirò G; Sturkenboom M;
Osteoporos Int; 2016 May; 27(5):1857-67. PubMed ID: 26694594
[TBL] [Abstract][Full Text] [Related]
17. Meta-analysis: oral bisphosphonates and the risk of oesophageal cancer.
Andrici J; Tio M; Eslick GD
Aliment Pharmacol Ther; 2012 Oct; 36(8):708-16. PubMed ID: 22966908
[TBL] [Abstract][Full Text] [Related]
18. A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics.
Pazianas M; Miller P; Blumentals WA; Bernal M; Kothawala P
Clin Ther; 2007 Aug; 29(8):1548-58. PubMed ID: 17919538
[TBL] [Abstract][Full Text] [Related]
19. A systematic review and economic evaluation of bisphosphonates for the prevention of fragility fractures.
Davis S; Martyn-St James M; Sanderson J; Stevens J; Goka E; Rawdin A; Sadler S; Wong R; Campbell F; Stevenson M; Strong M; Selby P; Gittoes N
Health Technol Assess; 2016 Oct; 20(78):1-406. PubMed ID: 27801641
[TBL] [Abstract][Full Text] [Related]
20. Bisphosphonates for breast cancer.
Pavlakis N; Schmidt R; Stockler M
Cochrane Database Syst Rev; 2005 Jul; (3):CD003474. PubMed ID: 16034900
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
